Related Experiment Videos
Summary
Intravenous immune globulin (IV-IgG) provides substitution therapy for immunodeficiencies and treats idiopathic thrombocytopenic purpura (ITP). Dosage varies, with caution advised for initial infusions in immunodeficient patients due to potential adverse reactions.
Area of Science:
- Immunology
- Pharmacology
Background:
- Intravenous immune globulin (IV-IgG) is a critical therapeutic agent.
- Approved indications include immunodeficiency syndromes and idiopathic thrombocytopenic purpura (ITP).
Purpose of the Study:
- To outline the approved dosing and administration guidelines for IV-IgG.
- To highlight safety considerations for specific patient populations.
Main Methods:
- Review of established therapeutic protocols for IV-IgG.
- Analysis of adverse reaction profiles in different patient groups.
Main Results:
- Substitution therapy doses range from 0.2-0.3 g/kg monthly or bi-weekly.
- ITP treatment involves 0.4 g/kg daily for 2-5 days, with repeat doses for maintenance.
- Initial infusions in immunodeficient patients require caution due to complement-mediated reactions.
Conclusions:
- IV-IgG has defined therapeutic uses and dosages for specific conditions.
- Patient-specific factors, such as prior treatment and IgA status, influence administration safety.
- Contraindications include selective IgA deficiency with detectable IgA antibodies.